Synthesis of Alkenylarylpyrazole Derivatives
Butyl (E)-3-[5-Methoxy-2-(1H-pyrazol-1-yl)phenyl]acrylate (6b): 1-{2,6-Bis[(E)-2-(butoxycarbonyl)ethenyl]-4-methoxyphenyl}-1H-
The general procedure was followed by using 1-(4-methoxyphenyl)
pyrazole (1b; 87 mg, 0.5 mmol) and butyl acrylate (5a; 0.049 mL,
pyrazole (6g): The general procedure was followed by using 1-(4-
methoxyphenyl)pyrazole (1b; 87 mg, 0.5 mmol) and butyl acrylate
0
.55 mmol). Purification by column chromatography (hexane/
(5a; 0.147 mL, 1.5 mmol). Purification by column chromatography
1
1
EtOAc, 90:10) yielded 6b (92%). H NMR (300 MHz, CDCl
7.79 (d, 1 H), 7.56 (d, 1 H); 7.37 (d, 1 H), 7.17 (d, 1 H), 7.04 (d,
J = 16.0 Hz, 1 H), 7.00 (dd, 1 H), 6.52 (t, 1 H), 6.27 (d, J = 16.0 Hz,
3
): δ (petroleum ether/Et
2
O, 90:10) yielded 6g (81 %). H NMR
=
(300 MHz, CDCl
3
): δ = 7.8 (d 1 H), 7.47 (d, 1 H), 7.22 (s, 2 H),
7.04 (d, J = 16.02 Hz, 1 H), 6.52 (t, 1 H), 6.27 (d, J = 16.02 Hz, 2
1
2
1
6
H), 4.12 (t, 2 H), 3.91 (s,3 H), 1.63–1.58 (m, 2 H), 1.39–1.35 (m,
H), 4.12 (t, 4 H), 3.92 (s, 3 H), 1.65–1.59 (m, 4 H), 1.40–1.34 (m,
4 H), 0.93 (t, 6 H) ppm. C NMR (75 MHz, CDCl ): δ = 166.02,
3
159.66, 141.15, 138.50, 134.66, 133.00, 132.22, 121.80, 113.11,
H), 0.88 (t, 3 H) ppm. 13C NMR (75 MHz, CDCl
13
3
): δ = 166.1,
59.7, 141.2, 138.5, 129.5, 127.8, 120.9, 116.3, 113.2, 111.6, 107.1,
+
4.5, 55.6, 31.9, 19.1, 13.6 ppm. MS (ESI): m/z = 301 [M + H] .
107.02, 64.41, 55.65, 30.46, 18.99, 13.58 ppm. MS (ESI): m/z = 427
+
+
31 5 2
H O N
[M + H]+ 427.2204;
HRMS: calcd. for C17
01.15467.
H
21
O
3
N
2
[M + H] 301.15522; found
[M + H] . HRMS: calcd. for C24
found 427.22275.
3
Butyl (E)-3-[5-Fluoro-2-(1H-pyrazol-1-yl)phenyl]acrylate (6c): The Butyl (2E)-3-[2-(4,5-Dihydrooxazol-2-yl)phenyl]acrylate (6h): The
general procedure was followed by using 1-(4-fluorophenyl)pyr-
azole (1c; 87 mg, 0.5 mmol) and butyl acrylate (5a; 0.049 mL,
general procedure was followed by using 2-phenyloxazoline (1g;
66 μL, 0.5 mmol), butyl acrylate (5a; 0.07 mL, 0.55 mmol), and eth-
0
.55 mmol). Purification by column chromatography (hexane/
anol (2 mL). Purification by column chromatography (hexane/
1
1
EtOAc, 90:10) yielded 6g (77%). H NMR (300 MHz, CDCl
3
): δ EtOAc, 70:30) yielded 6h (59%). H NMR (300 MHz, CDCl
3
): δ
=
7.76 (d,1 H), 7.79 (d,1 H), 7.48 (d, J = 16.0 Hz, 1 H), 7.45–7.38 = 8.53 (d, J = 16.0 Hz, 1 H), 7.86 (dd, 1 H), 7.65 (dd, 1 H), 7.51–
m, 2 H), 7.20–7.15 (m, 1 H), 6.49 (t, 1 H), 6.36 (d, J = 16.0 Hz, 1 7.41 (m, 2 H), 6.36 (d, J = 16.0 Hz, 1 H), 4.45 (t, 2 H), 4.21 (t, 2
H), 4.16 (t, 2 H), 1.67–1.61 (m, 2 H), 1.44–1.35 (m, 2 H), 0.94 (t, H), 4.07 (t, 2 H), 1.73–1.65 (m, 2 H), 1.49–1.43 (m, 2 H), 0.97 (t,
(
13
3
1
1
H) ppm. 13C NMR (75 MHz, CDCl
07.4, 114.5, 114.8, 117.3, 121.9, 128.7, 133.0, 138.6, 141.6, 160.7,
3
): δ = 13.6, 19.0, 30.5, 64.6, 3 H) ppm. C NMR (75 MHz, CDCl
135.0, 131.8, 130.8, 130.0, 127.4, 127.2, 120.1, 67.4, 65.0, 55.3, 30.7,
3
): δ = 166.9, 164.0, 143.6,
+
+
64.0, 165.7 ppm. MS (ESI): m/z = 289 [M + H] . HRMS: calcd. 19.1, 13.7 ppm. MS (ESI): m/z = 274 [M + H] . HRMS: calcd. for
+
16 20 3
C H O
N [M + H]+ 274.14375; found 274.14377.
for C16
H
18FN
2
O
2
[M + H] 289.13468; found 289.13335.
Butyl (E)-3-[2-Fluoro-6-(1H-pyrazol-1-yl)phenyl]acrylate (6d): The Butyl (2E)-3-[2-(4,5-Dihydro-4,4-dimethyloxazol-2-yl)phenyl]acryl-
general procedure was followed by using 1-(3-fluorophenyl)pyr-
azole (1d; 87 mg, 0.5 mmol) and butyl acrylate (5a; 0.049 mL,
ate (6i): The general procedure was followed by using 4,4-dimethyl-
2-phenyl-2-oxazoline (1h; 66 μL, 0.5 mmol), butyl acrylate (5a;
0
.55 mmol). Purification by column chromatography (hexane/
0.07 mL, 0.55 mmol), and ethanol (2 mL). Purification by column
1
1
EtOAc, 90:10) yielded 6d (68%). H NMR (300 MHz, CDCl
3
): δ chromatography (hexane/EtOAc, 70:30) yielded 6h (53%). H NMR
=
1
=
2
7.79 (d, 1 H), 7.70 (m, 1 H), 7.64 (d, 1 H), 7.60 (d, J = 16.021 Hz,
H), 7.25 (dd, 1 H), 7.17–7.13 (m, 1 H), 6.51 (t, 1 H), 6.34 (d, J 7.65 (dd, 1 H), 7.48–7.38 (m, 2 H), 6.37 (d, J = 16 Hz, 1 H), 4.21
16.021 Hz, 1 H), 4.17 (t, 2 H), 1.68–1.61 (m, 2 H), 1.43–1.37 (m, (t, 2 H), 4.13 (s, 2 H), 1.72–1.65 (m,2 H), 1.50–1.45 (m, 2 H), 1.25
H), 0.95 (t, 3 H) ppm. 13C NMR (75 MHz, CDCl
): δ = 13.7,
3
(300 MHz, CDCl ): δ = 8.48 (d, J = 16.0 Hz, 1 H), 7.81 (dd, 1 H),
13
3
3
(s, 6 H), 0.97 (t, 3 H) ppm. C NMR (75 MHz, CDCl ): δ = 166.9,
1
1
9.1, 30.5, 64.6, 107.6, 113.2, 113.5, 115.5, 115.9, 116.2, 117.5,
161.4, 143.2, 134.7, 130.7, 130.0, 129.3, 128.1, 127.0, 120.0, 79.0,
25.7, 125.9, 132.5, 135.4, 137.7, 141.6, 160.1, 163.6, 166.4 ppm.
68.3, 64.3, 30.7, 28.3, 19.2, 13.7 ppm. MS (ESI): m/z = 302 [M +
+
+
24 3
H O
N [M + H]+ 302.17429; found
MS (ESI): m/z = 289 [M + H] . HRMS: calcd. for C16
H
18FN
2
O
2
H] . HRMS: calcd. for C18
302.17507.
[
M + H]+ 289.13335; found 289.13468.
1
-{2,6-Bis[(E)-2-(butoxycarbonyl)ethenyl]-4-fluorophenyl}-1H-pyr- 1-{2,6-Bis[(E)-2-(Butoxycarbonyl)ethenyl]-4-acetylphenyl}-1H-pyr-
azole (6e): The general procedure was followed by using 1-(4-
fluorophenyl)pyrazole (1c; 87 mg, 0.5 mmol) and butyl acrylate
azole (6k): The general procedure was followed by using 1-[4-(1H-
pyrazol-1-yl)phenyl]ethanone (1e; 93 mg, 0.5 mmol) and butyl ac-
rylate (5a; 0.147 mL, 1.5 mmol). Purification by column
(
(
5a; 0.147 mL, 1.5 mmol). Purification by column chromatography
hexane/EtOAc, 90:10) yielded 6e (73 %). H NMR (300 MHz,
1
1
chromatography (hexane/EtOAc, 70:30) yielded 6k (83 %). H
CDCl
3 3
): δ = 7.82 (d, 1 H); 7.49 (d, 1 H), 7.02 (d, J = 16.017 Hz, 2 NMR (300 MHz, CDCl ): δ = 8.28 (s, 2 H), 7.86 (d, 1 H), 7.53 (d,
H), 6.55 (t, 1 H), 6.30 (d, J = 16.017 Hz, 2 H); 4.13 (t, 4 H), 1.64– 1 H), 7.15 (d, J = 16 Hz, 2 H), 6.58 (t, 1 H), 6.42 (d, J = 16 Hz, 2
1
3
1
(
1
.58 (m, 4 H), 1.39–1.33 (m, 4 H), 0.93 (t, 6 H) ppm. C NMR
75 MHz, CDCl ): δ = 166.0, 164.0, 141.8, 137.7, 133.3, 131.8, 4 H), 0.94 (t,6 H) ppm. C NMR (75 MHz, CDCl
23.2, 114.7, 115.1, 107.7, 64.9, 30.8, 19.3, 13.9 ppm. MS (ESI): 165.8, 141.9, 138.0, 134.0, 132.7, 128.5, 127.8, 122.9, 107.7, 64.7,
H), 4.15 (t, 4 H), 2.71 (s, 3 H), 1.65–1.42 (m, 4 H), 1.41–1.37 (m,
1
3
3
3
): δ = 196.0,
+
[M + H]+
+
m/z = 415 [M + H] . HRMS: calcd. for C23
4
H
28FN
2
O
4
31.9, 30.5, 19.1, 13.6 ppm. MS (ESI): m/z = 439 [M + H] . HRMS:
15.20413; found 415.20276.
calcd. for C25
31 5 2
H O N
[M + H]+ 439.22262; found 439.22275.
1
-{2,6-Bis[(E)-2-(butoxycarbonyl)ethenyl]-3-fluorophenyl}-1H-pyr- 1-{2,6-Bis[(E)-2-(Butoxycarbonyl)ethenyl]benzamidophenyl}-1H-pyr-
azole (6f): The general procedure was followed by using 1-(3-fluoro-
phenyl)pyrazole (1d; 87 mg, 0.5 mmol) and butyl acrylate (5a;
azole (6l): The general procedure was followed by using 4-(1H-pyr-
azol-1-yl)benzonitrile (1g; 43 mg, 0.25 mmol) and butyl acrylate
(5a; 0.147 mL, 1.5 mmol). Purification by column chromatography
0
.147 mL, 1.5 mmol). Purification by column chromatography
1
1
(
hexane/EtOAc, 90:10) yielded 6f (38 %). H NMR (300 MHz,
CDCl ): δ = 7.84 (d, 1 H), 7.70 (dd, 1 H), 7.51 (d, 1 H), 7.33–7.27
m, 2 H), 6.98 (dd, 2 H), 6.56 (t, 1 H), 6.31 (dd, 2 H), 4.31 (t, 4
(hexane/EtOAc, 70:30) yielded 6l (76 %). H NMR (300 MHz,
3
CDCl
3
): δ = 8.16 (s, 2 H), 7.85 (d, 1 H), 7.52 (d, 1 H), 7.11 (d, J
(
= 16 Hz, 2 H), 6.58 (t, 1 H), 6.41 (d, J = 16 Hz, 2 H), 4.14 (t, 4
1
3
13
H), 1.64–1.57 (m, 4 H), 1.40–1.33 (m, 4 H), 0.93 (t, 6 H) ppm.
C
H), 1.66–1.58 (m, 4 H), 1.42–1.34 (m, 4 H), 0.93 (t, 6 H) ppm.
): δ = 167.4, 165.9, 141.8, 140.8, 137.8,
134.5, 133.9, 132.8, 127.1, 122.8, 107.7, 64.6, 30.5, 19.6,13.6 ppm.
C
NMR (75 MHz, CDCl ): δ = 166.4, 163.6, 160.1, 141.6, 137.7, NMR (75 MHz, CDCl
3
3
1
3
32.5, 128.5, 125.9, 121.5, 117.5, 116.2, 115.9, 115.5, 107.6, 64.6,
+
+
0.5, 19.1, 13.7 ppm. MS (ESI): m/z = 415 [M + H] . HRMS:
29 3 5
MS (ESI): m/z = 440 [M + H] . HRMS: calcd. for C24H N O
+
[M + H]+ 440.21738; found 440.21800.
calcd. for C23
H
28FN
2
O
4
[M + H] 415.20413; found 415.20276.
Eur. J. Org. Chem. 2015, 6025–6032
© 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.eurjoc.org
6031